Affiliations
Division of General Internal Medicine, Department of Medicine, McGill University Health Centre
McGill Centre for Quality Improvement
Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Canada
Given name(s)
Todd C.
Family name
Lee
Degrees
MD, MPH

Catheter Use Among Teaching Hospitals

Article Type
Changed
Wed, 01/04/2017 - 11:35
Display Headline
A point prevalence study of urinary catheter use among teaching hospitals with and without reduction programs

Urinary catheter use can be associated with urinary tract infections, delirium, trauma, and immobility.[1] Evidence‐based strategies to reduce inappropriate use are available[2]; however, their application across centers is variable.[3] We aimed to characterize the prevalence and indication for catheters among Canadian teaching hospitals with and without catheter reduction programs.

METHODS

Twelve of 17 postgraduate internal medicine training program directors agreed to participate, and 9 Canadian teaching hospitals enrolled in this prevalence study of urinary catheter use among medical inpatients. Data collection used a standardized form and took place over 5 consecutive weekdays during August 2015. Each site anonymously collected the total number of catheters, total number of inpatient‐days, and indications for use from either the bedside nurse or physician. Appropriate clinical indications were based on the 2009 guidelines from the Healthcare Infection Control Practice Advisory Committee.[4] Potentially inappropriate indications included urine output measurement in noncritically ill patients, and other or unknown indications.[4, 5] A catheter reduction program was defined as the presence of a structured system to monitor and reduce use via: nurse‐directed catheter removal, audit‐feedback of use to providers, physician reminders, and/or automatic stop orders.

The primary outcome was the number of catheter days per 100 inpatient‐days. We used generalized estimating equations to adjust the 95% confidence interval (CI) and P value to account for hospital‐level clustering of the responses. The P values are from a 2‐tailed Wald test against the true log scale parameter being equal to zero. The analysis was performed using R version 3.0.2 using the geepack package (Free Software Foundation, Boston, MA).

The McGill University Health Centre Research Ethics Board approved this study with concomitant authorization at participating sites.

RESULTS

The characteristics of participating hospitals are displayed in Table 1. Those with active catheter reduction programs reported established systems for monitoring catheter placement, duration, and catheter‐associated urinary tract infections. More than half of the hospitals lacked a catheter reduction program. Overall, catheters were present on 13.6% of patient‐days (range, 2.3%32.4%). Centers without reduction programs reported higher rates of catheter use both overall and for potentially inappropriate indications. After adjustment for clustering, those with a formal intervention had 8.8 fewer catheter days per 100 patient‐days as compared to those without (9.8 [95% CI: 6.0‐15.6] vs 18.6 [95% CI: 13.0‐26.1], P = 0.03). This meant that the odds of a urinary catheter being present were 2 times (95% CI: 1.0‐3.4) greater in hospitals without reduction programs. Differences in appropriate catheter use did not reach statistical significance.

Urinary Catheter Prevalence and Indication in Nine Urban Canadian Hospitals
CharacteristicHospitalOverall, n (%)*
ABCDEFGHI
  • NOTE: Catheter inserted for the following indications: obstruction = bladder outlet obstruction; retention = acute urinary retention; palliative = indications to achieve comfort for patients at the end of life; sacral ulcer = to allow healing of stage 3 or 4 sacral ulcers in incontinent patients; urine output = to monitor strict urinary output ; other = indications exclusive of the specified indications; unknown = the provider is unaware of indications for insertion. Abbreviations: N/A, not applicable; UC, urinary catheter. *Percentages are row percentages. Nurse directive. Physician reminder. Audit feedback. ∥Reported historical rates by hospital (A: 2013 point prevalence rate; B: 2013 mean; C: 2014 point prevalence rate). Percentages are column percentages with total UC days as denominator and sum total may exceed 100% if patients had more than 1 indication specified.

Total beds, n4425338245052729256507774465,374
Has system in place to monitor urinary catheter placementYesYesYesYesNoNoNoNoNoN/A
Has system in place to monitor duration and/or discontinuation of urinary cathetersYesYesYesNoNoNoNoNoNoN/A
Has a system in place for monitoring catheter associated urinary tract infection ratesYesYesYesYesYesYesYesNoNoN/A
Presence of a UC reduction programActiveActiveActiveActiveNoNoNoNoNoN/A
Duration of UC reduction program, y1211N/AN/AN/AN/AN/AN/A
Total patient‐days425455527405873112853942533142
Total UC days27324277236488082426
UC rate per 100 patient‐days6.47.08.019.02.311.616.820.332.413.6
Reported historical UC rate per 100 patient‐days∥12.016.518.8N/AN/AN/AN/AN/AN/AN/A
Potentially appropriate indications, n (%)19 (70)25 (78)30 (71)36 (47)033 (92)27 (56)32 (40)59 (72)261 (61)
Obstruction5 (19)11 (34)19 (45)7 (9)01 (3)10 (21)20 (25)2 (2)75 (17.6)
Retention10 (37)9 (28)7 (17)21 (27)022 (61)9 (19)11 (14)23 (28)112 (26.3)
Palliative4 (15)04 (10)8 (10)010 (28)5 (10)1 (1)16 (20)93 (21.8)
Sacral ulcer05 (16)00003 (6)018 (22)26 (6.1)
Potentially inappropriate indications, n (%)8 (30)8 (25)12 (28)50 (65)2 (100)3 (8)21 (44)70 (88)16 (20)190 (45)
Urine output2 (7)01 (2)22 (14)2 (100)3 (8)11 (23)50 (35)8 (10)96 (22.5)
Other6 (22)8 (25)10 (24)26 (32)005 (10)13 (16)068 (16.0)
Unknown001 (2)2 (3)005 (10)7 (9)8 (10)23 (5.3)

DISCUSSION

Despite the availability of consensus guidelines for appropriate use and the efforts of movements like Choosing Wisely, many Canadian teaching hospitals have not yet established a urinary catheter reduction program for medical inpatients. Our findings are similar to 2 non‐Canadian studies, which demonstrated that fewer than half of hospitals had implemented control measures.[4, 6] In contrast to those other studies, our study demonstrated that hospitals that employed control measures had reduced rates of catheter use suggesting that systematic, structured efforts are necessary to improve practice.[7, 8]

Ours is the first nation‐wide study in Canada to report urinary catheter rates and the effect of associated reduction programs. Data from the National Healthcare Safety Network suggest our Canadian estimates of urinary catheter rates in medical inpatients are similar to those of the United States (13.6 vs 14.8 catheter days per 100 inpatient‐days, respectively, for general medical inpatients).[9, 10]

Several limitations of this study warrant discussion. First, we sampled only academic institutions at 1 time point, which may not represent annualized rates or rates in community hospitals. However, our findings are similar to those reported in previous studies.[10] Second, our method of consecutive daily audits may have caused individuals to change their behavior knowing that they were being observed, resulting in lower catheter utilization than would have been otherwise present and biasing our estimates of catheter overuse downward. Third, we collected point prevalence data, limiting our ability to make inferences on causality. The key factor(s) contributing to observed differences between hospitals remains unknown. However, pre‐post intervention data available for 3 hospitals suggest that improvements followed active catheter reduction efforts.[7, 8] Fourth, we were unable to obtain outcome data such as catheter‐associated urinary tract infection, delirium, or fall rates. However, catheter reduction is widely recognized as an important first step to reducing preventable harm for hospital patients.

We suggest that the broader uptake of structured models of care that promote early discontinuation of urinary catheters on medical wards is needed to improve their appropriateness. Fortunately, it appears as though a variety of models are effective. Therefore, when it comes to adopting Choosing Wisely's less is more philosophy toward urinary catheter utilization, we suggest that less time be allowed to pass before more proven and structured interventions are universally implemented.

Acknowledgements

The authors are indebted to John Matelski, MSc, for statistical analyses.

Disclosures: The Canadian Society of Internal Medicine and its Choosing Wisely Canada Subcommittee supported this work. The authors report no conflicts of interest.

Files
References
  1. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter‐associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625663.
  2. Lo E, Nicolle LE, Coffin SE, et al. Strategies to prevent catheter‐associated urinary tract infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(5):464479.
  3. Saint S, Greene MT, Kowalski CP, et al. Preventing catheter‐associated urinary tract infection in the United States: a national comparative study. JAMA Intern Med. 2013;173(10):874879.
  4. Gould CV, Umscheid CA, Agarwal RK, et al, Healthcare Infection Control Practices Advisory Committee. Guideline for prevention of catheter‐associated urinary tract infections 2009. Infect Control Hosp Epidemiol. 2010;31(4):319326.
  5. Saint S, Wiese J, Amory JK, et al. Are physicians aware of which of their patients have indwelling urinary catheters? Am J Med. 2000;109(6):476480.
  6. Conway LJ, Pogorzelska M, Larson E, et al. Adoption of policies to prevent catheter‐associated urinary tract infections in United States intensive care units. Am J Infect Control. 2012;40(8):705710.
  7. Leis JA, Corpus C, Rahmani A, et al. Medical directive for urinary catheter removal by nurses on general medical wards. JAMA Intern Med. 2016;176(1):113115.
  8. Schwartz BC, Frenette C, Lee TC, et al. Novel low‐resource intervention reduces urinary catheter use and associated urinary tract infections: role of outcome measure bias? Am J Infect Control. 2015;43(4):348353.
  9. Dudeck MA, Edwards JR, Allen-Bridson K, et al. National Healthcare Safety Network report, data summary for 2013, Device-associated Module. Am J Infect Control. 2015;43(3):206221.
  10. Greene MT, Fakih MG, Fowler KE, et al. Regional variation in urinary catheter use and catheter‐associated urinary tract infection: results from a national collaborative. Infect Control Hosp Epidemiol. 2014;35(suppl 3):S99S106.
Article PDF
Issue
Journal of Hospital Medicine - 11(11)
Publications
Page Number
799-800
Sections
Files
Files
Article PDF
Article PDF

Urinary catheter use can be associated with urinary tract infections, delirium, trauma, and immobility.[1] Evidence‐based strategies to reduce inappropriate use are available[2]; however, their application across centers is variable.[3] We aimed to characterize the prevalence and indication for catheters among Canadian teaching hospitals with and without catheter reduction programs.

METHODS

Twelve of 17 postgraduate internal medicine training program directors agreed to participate, and 9 Canadian teaching hospitals enrolled in this prevalence study of urinary catheter use among medical inpatients. Data collection used a standardized form and took place over 5 consecutive weekdays during August 2015. Each site anonymously collected the total number of catheters, total number of inpatient‐days, and indications for use from either the bedside nurse or physician. Appropriate clinical indications were based on the 2009 guidelines from the Healthcare Infection Control Practice Advisory Committee.[4] Potentially inappropriate indications included urine output measurement in noncritically ill patients, and other or unknown indications.[4, 5] A catheter reduction program was defined as the presence of a structured system to monitor and reduce use via: nurse‐directed catheter removal, audit‐feedback of use to providers, physician reminders, and/or automatic stop orders.

The primary outcome was the number of catheter days per 100 inpatient‐days. We used generalized estimating equations to adjust the 95% confidence interval (CI) and P value to account for hospital‐level clustering of the responses. The P values are from a 2‐tailed Wald test against the true log scale parameter being equal to zero. The analysis was performed using R version 3.0.2 using the geepack package (Free Software Foundation, Boston, MA).

The McGill University Health Centre Research Ethics Board approved this study with concomitant authorization at participating sites.

RESULTS

The characteristics of participating hospitals are displayed in Table 1. Those with active catheter reduction programs reported established systems for monitoring catheter placement, duration, and catheter‐associated urinary tract infections. More than half of the hospitals lacked a catheter reduction program. Overall, catheters were present on 13.6% of patient‐days (range, 2.3%32.4%). Centers without reduction programs reported higher rates of catheter use both overall and for potentially inappropriate indications. After adjustment for clustering, those with a formal intervention had 8.8 fewer catheter days per 100 patient‐days as compared to those without (9.8 [95% CI: 6.0‐15.6] vs 18.6 [95% CI: 13.0‐26.1], P = 0.03). This meant that the odds of a urinary catheter being present were 2 times (95% CI: 1.0‐3.4) greater in hospitals without reduction programs. Differences in appropriate catheter use did not reach statistical significance.

Urinary Catheter Prevalence and Indication in Nine Urban Canadian Hospitals
CharacteristicHospitalOverall, n (%)*
ABCDEFGHI
  • NOTE: Catheter inserted for the following indications: obstruction = bladder outlet obstruction; retention = acute urinary retention; palliative = indications to achieve comfort for patients at the end of life; sacral ulcer = to allow healing of stage 3 or 4 sacral ulcers in incontinent patients; urine output = to monitor strict urinary output ; other = indications exclusive of the specified indications; unknown = the provider is unaware of indications for insertion. Abbreviations: N/A, not applicable; UC, urinary catheter. *Percentages are row percentages. Nurse directive. Physician reminder. Audit feedback. ∥Reported historical rates by hospital (A: 2013 point prevalence rate; B: 2013 mean; C: 2014 point prevalence rate). Percentages are column percentages with total UC days as denominator and sum total may exceed 100% if patients had more than 1 indication specified.

Total beds, n4425338245052729256507774465,374
Has system in place to monitor urinary catheter placementYesYesYesYesNoNoNoNoNoN/A
Has system in place to monitor duration and/or discontinuation of urinary cathetersYesYesYesNoNoNoNoNoNoN/A
Has a system in place for monitoring catheter associated urinary tract infection ratesYesYesYesYesYesYesYesNoNoN/A
Presence of a UC reduction programActiveActiveActiveActiveNoNoNoNoNoN/A
Duration of UC reduction program, y1211N/AN/AN/AN/AN/AN/A
Total patient‐days425455527405873112853942533142
Total UC days27324277236488082426
UC rate per 100 patient‐days6.47.08.019.02.311.616.820.332.413.6
Reported historical UC rate per 100 patient‐days∥12.016.518.8N/AN/AN/AN/AN/AN/AN/A
Potentially appropriate indications, n (%)19 (70)25 (78)30 (71)36 (47)033 (92)27 (56)32 (40)59 (72)261 (61)
Obstruction5 (19)11 (34)19 (45)7 (9)01 (3)10 (21)20 (25)2 (2)75 (17.6)
Retention10 (37)9 (28)7 (17)21 (27)022 (61)9 (19)11 (14)23 (28)112 (26.3)
Palliative4 (15)04 (10)8 (10)010 (28)5 (10)1 (1)16 (20)93 (21.8)
Sacral ulcer05 (16)00003 (6)018 (22)26 (6.1)
Potentially inappropriate indications, n (%)8 (30)8 (25)12 (28)50 (65)2 (100)3 (8)21 (44)70 (88)16 (20)190 (45)
Urine output2 (7)01 (2)22 (14)2 (100)3 (8)11 (23)50 (35)8 (10)96 (22.5)
Other6 (22)8 (25)10 (24)26 (32)005 (10)13 (16)068 (16.0)
Unknown001 (2)2 (3)005 (10)7 (9)8 (10)23 (5.3)

DISCUSSION

Despite the availability of consensus guidelines for appropriate use and the efforts of movements like Choosing Wisely, many Canadian teaching hospitals have not yet established a urinary catheter reduction program for medical inpatients. Our findings are similar to 2 non‐Canadian studies, which demonstrated that fewer than half of hospitals had implemented control measures.[4, 6] In contrast to those other studies, our study demonstrated that hospitals that employed control measures had reduced rates of catheter use suggesting that systematic, structured efforts are necessary to improve practice.[7, 8]

Ours is the first nation‐wide study in Canada to report urinary catheter rates and the effect of associated reduction programs. Data from the National Healthcare Safety Network suggest our Canadian estimates of urinary catheter rates in medical inpatients are similar to those of the United States (13.6 vs 14.8 catheter days per 100 inpatient‐days, respectively, for general medical inpatients).[9, 10]

Several limitations of this study warrant discussion. First, we sampled only academic institutions at 1 time point, which may not represent annualized rates or rates in community hospitals. However, our findings are similar to those reported in previous studies.[10] Second, our method of consecutive daily audits may have caused individuals to change their behavior knowing that they were being observed, resulting in lower catheter utilization than would have been otherwise present and biasing our estimates of catheter overuse downward. Third, we collected point prevalence data, limiting our ability to make inferences on causality. The key factor(s) contributing to observed differences between hospitals remains unknown. However, pre‐post intervention data available for 3 hospitals suggest that improvements followed active catheter reduction efforts.[7, 8] Fourth, we were unable to obtain outcome data such as catheter‐associated urinary tract infection, delirium, or fall rates. However, catheter reduction is widely recognized as an important first step to reducing preventable harm for hospital patients.

We suggest that the broader uptake of structured models of care that promote early discontinuation of urinary catheters on medical wards is needed to improve their appropriateness. Fortunately, it appears as though a variety of models are effective. Therefore, when it comes to adopting Choosing Wisely's less is more philosophy toward urinary catheter utilization, we suggest that less time be allowed to pass before more proven and structured interventions are universally implemented.

Acknowledgements

The authors are indebted to John Matelski, MSc, for statistical analyses.

Disclosures: The Canadian Society of Internal Medicine and its Choosing Wisely Canada Subcommittee supported this work. The authors report no conflicts of interest.

Urinary catheter use can be associated with urinary tract infections, delirium, trauma, and immobility.[1] Evidence‐based strategies to reduce inappropriate use are available[2]; however, their application across centers is variable.[3] We aimed to characterize the prevalence and indication for catheters among Canadian teaching hospitals with and without catheter reduction programs.

METHODS

Twelve of 17 postgraduate internal medicine training program directors agreed to participate, and 9 Canadian teaching hospitals enrolled in this prevalence study of urinary catheter use among medical inpatients. Data collection used a standardized form and took place over 5 consecutive weekdays during August 2015. Each site anonymously collected the total number of catheters, total number of inpatient‐days, and indications for use from either the bedside nurse or physician. Appropriate clinical indications were based on the 2009 guidelines from the Healthcare Infection Control Practice Advisory Committee.[4] Potentially inappropriate indications included urine output measurement in noncritically ill patients, and other or unknown indications.[4, 5] A catheter reduction program was defined as the presence of a structured system to monitor and reduce use via: nurse‐directed catheter removal, audit‐feedback of use to providers, physician reminders, and/or automatic stop orders.

The primary outcome was the number of catheter days per 100 inpatient‐days. We used generalized estimating equations to adjust the 95% confidence interval (CI) and P value to account for hospital‐level clustering of the responses. The P values are from a 2‐tailed Wald test against the true log scale parameter being equal to zero. The analysis was performed using R version 3.0.2 using the geepack package (Free Software Foundation, Boston, MA).

The McGill University Health Centre Research Ethics Board approved this study with concomitant authorization at participating sites.

RESULTS

The characteristics of participating hospitals are displayed in Table 1. Those with active catheter reduction programs reported established systems for monitoring catheter placement, duration, and catheter‐associated urinary tract infections. More than half of the hospitals lacked a catheter reduction program. Overall, catheters were present on 13.6% of patient‐days (range, 2.3%32.4%). Centers without reduction programs reported higher rates of catheter use both overall and for potentially inappropriate indications. After adjustment for clustering, those with a formal intervention had 8.8 fewer catheter days per 100 patient‐days as compared to those without (9.8 [95% CI: 6.0‐15.6] vs 18.6 [95% CI: 13.0‐26.1], P = 0.03). This meant that the odds of a urinary catheter being present were 2 times (95% CI: 1.0‐3.4) greater in hospitals without reduction programs. Differences in appropriate catheter use did not reach statistical significance.

Urinary Catheter Prevalence and Indication in Nine Urban Canadian Hospitals
CharacteristicHospitalOverall, n (%)*
ABCDEFGHI
  • NOTE: Catheter inserted for the following indications: obstruction = bladder outlet obstruction; retention = acute urinary retention; palliative = indications to achieve comfort for patients at the end of life; sacral ulcer = to allow healing of stage 3 or 4 sacral ulcers in incontinent patients; urine output = to monitor strict urinary output ; other = indications exclusive of the specified indications; unknown = the provider is unaware of indications for insertion. Abbreviations: N/A, not applicable; UC, urinary catheter. *Percentages are row percentages. Nurse directive. Physician reminder. Audit feedback. ∥Reported historical rates by hospital (A: 2013 point prevalence rate; B: 2013 mean; C: 2014 point prevalence rate). Percentages are column percentages with total UC days as denominator and sum total may exceed 100% if patients had more than 1 indication specified.

Total beds, n4425338245052729256507774465,374
Has system in place to monitor urinary catheter placementYesYesYesYesNoNoNoNoNoN/A
Has system in place to monitor duration and/or discontinuation of urinary cathetersYesYesYesNoNoNoNoNoNoN/A
Has a system in place for monitoring catheter associated urinary tract infection ratesYesYesYesYesYesYesYesNoNoN/A
Presence of a UC reduction programActiveActiveActiveActiveNoNoNoNoNoN/A
Duration of UC reduction program, y1211N/AN/AN/AN/AN/AN/A
Total patient‐days425455527405873112853942533142
Total UC days27324277236488082426
UC rate per 100 patient‐days6.47.08.019.02.311.616.820.332.413.6
Reported historical UC rate per 100 patient‐days∥12.016.518.8N/AN/AN/AN/AN/AN/AN/A
Potentially appropriate indications, n (%)19 (70)25 (78)30 (71)36 (47)033 (92)27 (56)32 (40)59 (72)261 (61)
Obstruction5 (19)11 (34)19 (45)7 (9)01 (3)10 (21)20 (25)2 (2)75 (17.6)
Retention10 (37)9 (28)7 (17)21 (27)022 (61)9 (19)11 (14)23 (28)112 (26.3)
Palliative4 (15)04 (10)8 (10)010 (28)5 (10)1 (1)16 (20)93 (21.8)
Sacral ulcer05 (16)00003 (6)018 (22)26 (6.1)
Potentially inappropriate indications, n (%)8 (30)8 (25)12 (28)50 (65)2 (100)3 (8)21 (44)70 (88)16 (20)190 (45)
Urine output2 (7)01 (2)22 (14)2 (100)3 (8)11 (23)50 (35)8 (10)96 (22.5)
Other6 (22)8 (25)10 (24)26 (32)005 (10)13 (16)068 (16.0)
Unknown001 (2)2 (3)005 (10)7 (9)8 (10)23 (5.3)

DISCUSSION

Despite the availability of consensus guidelines for appropriate use and the efforts of movements like Choosing Wisely, many Canadian teaching hospitals have not yet established a urinary catheter reduction program for medical inpatients. Our findings are similar to 2 non‐Canadian studies, which demonstrated that fewer than half of hospitals had implemented control measures.[4, 6] In contrast to those other studies, our study demonstrated that hospitals that employed control measures had reduced rates of catheter use suggesting that systematic, structured efforts are necessary to improve practice.[7, 8]

Ours is the first nation‐wide study in Canada to report urinary catheter rates and the effect of associated reduction programs. Data from the National Healthcare Safety Network suggest our Canadian estimates of urinary catheter rates in medical inpatients are similar to those of the United States (13.6 vs 14.8 catheter days per 100 inpatient‐days, respectively, for general medical inpatients).[9, 10]

Several limitations of this study warrant discussion. First, we sampled only academic institutions at 1 time point, which may not represent annualized rates or rates in community hospitals. However, our findings are similar to those reported in previous studies.[10] Second, our method of consecutive daily audits may have caused individuals to change their behavior knowing that they were being observed, resulting in lower catheter utilization than would have been otherwise present and biasing our estimates of catheter overuse downward. Third, we collected point prevalence data, limiting our ability to make inferences on causality. The key factor(s) contributing to observed differences between hospitals remains unknown. However, pre‐post intervention data available for 3 hospitals suggest that improvements followed active catheter reduction efforts.[7, 8] Fourth, we were unable to obtain outcome data such as catheter‐associated urinary tract infection, delirium, or fall rates. However, catheter reduction is widely recognized as an important first step to reducing preventable harm for hospital patients.

We suggest that the broader uptake of structured models of care that promote early discontinuation of urinary catheters on medical wards is needed to improve their appropriateness. Fortunately, it appears as though a variety of models are effective. Therefore, when it comes to adopting Choosing Wisely's less is more philosophy toward urinary catheter utilization, we suggest that less time be allowed to pass before more proven and structured interventions are universally implemented.

Acknowledgements

The authors are indebted to John Matelski, MSc, for statistical analyses.

Disclosures: The Canadian Society of Internal Medicine and its Choosing Wisely Canada Subcommittee supported this work. The authors report no conflicts of interest.

References
  1. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter‐associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625663.
  2. Lo E, Nicolle LE, Coffin SE, et al. Strategies to prevent catheter‐associated urinary tract infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(5):464479.
  3. Saint S, Greene MT, Kowalski CP, et al. Preventing catheter‐associated urinary tract infection in the United States: a national comparative study. JAMA Intern Med. 2013;173(10):874879.
  4. Gould CV, Umscheid CA, Agarwal RK, et al, Healthcare Infection Control Practices Advisory Committee. Guideline for prevention of catheter‐associated urinary tract infections 2009. Infect Control Hosp Epidemiol. 2010;31(4):319326.
  5. Saint S, Wiese J, Amory JK, et al. Are physicians aware of which of their patients have indwelling urinary catheters? Am J Med. 2000;109(6):476480.
  6. Conway LJ, Pogorzelska M, Larson E, et al. Adoption of policies to prevent catheter‐associated urinary tract infections in United States intensive care units. Am J Infect Control. 2012;40(8):705710.
  7. Leis JA, Corpus C, Rahmani A, et al. Medical directive for urinary catheter removal by nurses on general medical wards. JAMA Intern Med. 2016;176(1):113115.
  8. Schwartz BC, Frenette C, Lee TC, et al. Novel low‐resource intervention reduces urinary catheter use and associated urinary tract infections: role of outcome measure bias? Am J Infect Control. 2015;43(4):348353.
  9. Dudeck MA, Edwards JR, Allen-Bridson K, et al. National Healthcare Safety Network report, data summary for 2013, Device-associated Module. Am J Infect Control. 2015;43(3):206221.
  10. Greene MT, Fakih MG, Fowler KE, et al. Regional variation in urinary catheter use and catheter‐associated urinary tract infection: results from a national collaborative. Infect Control Hosp Epidemiol. 2014;35(suppl 3):S99S106.
References
  1. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter‐associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625663.
  2. Lo E, Nicolle LE, Coffin SE, et al. Strategies to prevent catheter‐associated urinary tract infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(5):464479.
  3. Saint S, Greene MT, Kowalski CP, et al. Preventing catheter‐associated urinary tract infection in the United States: a national comparative study. JAMA Intern Med. 2013;173(10):874879.
  4. Gould CV, Umscheid CA, Agarwal RK, et al, Healthcare Infection Control Practices Advisory Committee. Guideline for prevention of catheter‐associated urinary tract infections 2009. Infect Control Hosp Epidemiol. 2010;31(4):319326.
  5. Saint S, Wiese J, Amory JK, et al. Are physicians aware of which of their patients have indwelling urinary catheters? Am J Med. 2000;109(6):476480.
  6. Conway LJ, Pogorzelska M, Larson E, et al. Adoption of policies to prevent catheter‐associated urinary tract infections in United States intensive care units. Am J Infect Control. 2012;40(8):705710.
  7. Leis JA, Corpus C, Rahmani A, et al. Medical directive for urinary catheter removal by nurses on general medical wards. JAMA Intern Med. 2016;176(1):113115.
  8. Schwartz BC, Frenette C, Lee TC, et al. Novel low‐resource intervention reduces urinary catheter use and associated urinary tract infections: role of outcome measure bias? Am J Infect Control. 2015;43(4):348353.
  9. Dudeck MA, Edwards JR, Allen-Bridson K, et al. National Healthcare Safety Network report, data summary for 2013, Device-associated Module. Am J Infect Control. 2015;43(3):206221.
  10. Greene MT, Fakih MG, Fowler KE, et al. Regional variation in urinary catheter use and catheter‐associated urinary tract infection: results from a national collaborative. Infect Control Hosp Epidemiol. 2014;35(suppl 3):S99S106.
Issue
Journal of Hospital Medicine - 11(11)
Issue
Journal of Hospital Medicine - 11(11)
Page Number
799-800
Page Number
799-800
Publications
Publications
Article Type
Display Headline
A point prevalence study of urinary catheter use among teaching hospitals with and without reduction programs
Display Headline
A point prevalence study of urinary catheter use among teaching hospitals with and without reduction programs
Sections
Article Source

© 2016 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Address for correspondence and reprint requests: Christine Soong, MD, Mount Sinai Hospital, 428‐600 University Avenue, Toronto, Ontario, Canada M5G 1X5; Telephone: 416‐586‐4800; Fax: 647‐776‐3148; E‐mail: christine.soong@utoronto.ca
Content Gating
Gated (full article locked unless allowed per User)
Gating Strategy
First Peek Free
Article PDF Media
Media Files

Reducing Inappropriate PPIs at Discharge

Article Type
Changed
Sun, 05/21/2017 - 13:12
Display Headline
Reduction of inappropriate exit prescriptions for proton pump inhibitors: A before‐after study using education paired with a web‐based quality‐improvement tool

In 2013, there were more than 15 million Americans receiving proton pump inhibitors (PPIs),[1] with an associated drug cost of nearly $79 billion between 2007 and 2011.2 PPI use is reaching epidemic proportions, likely due to the medicalization of gastrointestinal symptoms coupled with pervasive marketing and academic detailing being performed by the pharmaceutical industry.

Although PPIs are generally considered safe, they are not as innocuous as many physicians believe. In 2011 and 2012, the US Food and Drug Administration and Health Canada, respectively, issued safety advisories regarding the use of these medications related to Clostridium difficile, fracture risk, and electrolyte derangement.[3, 4, 5, 6] There have also been numerous other harmful associations reported,[7, 8, 9, 10] suggesting it would be prudent to follow Health Canada's advice that: PPIs should be prescribed at the lowest dose and shortest duration of therapy appropriate to the condition being treated.[4] In many cases this implies stopping the PPI after an appropriate duration of therapy or attempting nonpharmacological or H2‐blocker therapy instead.

Nevertheless, despite numerous cautionary publications, PPI use for nonevidence‐based indications remains common. Because they are generally thought of as outpatient medications, PPIs are frequently continued in hospitalized patients, and inappropriate outpatient therapy is rarely addressed.[11, 12, 13] Likewise, inappropriate de novo use can also be observed during hospitalization and may continue on discharge.[13, 14, 15] Hospitalization may consequently present an opportunity to employ meaningful interventions targeting outpatient medication use.[16] We developed an opportune inpatient intervention targeting inappropriate PPI therapy.

Our study had 2 aims: first, to determine the magnitude of the problem in a contemporary Canadian medical inpatient population, and second, we sought to leverage the inpatient admission as an opportunity to promote change when the patient returned to the community through the application of an educational and web‐based quality‐improvement (QI) intervention.

METHODS

Patient Inclusion

Between January 2012 and December 2012, we included all consecutively admitted patients on our 46‐bed general medical clinical teaching unit belonging to a 417‐bed tertiary care teaching hospital in Montreal, Canada. There were no exclusion criteria. This time period was divided into 2 blocks: the preintervention control period from January 1 to June 3 and the intervention period from June 4 to December 16.

Intervention and Implementation Strategy

At the start of each academic period, we presented a 20‐minute information session on the benefits and harms of PPI use (see Supporting Information, Appendix, in the online version of this article). The unit's medical residents and faculty attended these rounds. The presentation described the project, consensus‐derived indications for PPI use, and potential adverse events attributable to PPIs (see Table 1 for indications based on internal consensus and similar studies[17, 18, 19, 20, 21, 22, 23]). All other indications were considered nonevidence based. At the end of the month, teams were given feedback on indications they provided using the Web tool and the proportion of patients they discharged on a PPI with and without indication.

Consensus Indications for Proton Pump Inhibitors
  • NOTE: Abbreviations: NSAID, nonsteroidal anti‐inflammatory drug.

1. Gastric or duodenal ulcer within the past 3 months
2. Pathological hypersecretory conditions
3. Gastroesophageal reflux disease with exacerbations within the last 3 months not responsive to H2 blockers and nonpharmacologic techniques
4. Erosive esophagitis
5. Recurring symptoms recently associated with severe indigestion within the last 3 months not responsive to H2 blocker or nonpharmacologic techniques
6. Helicobacter pylori eradication
7. Dual antiplatelet therapy
8. Antiplatelet therapy with anticoagulants
9. Antiplatelet or anticoagulant therapy with history of previous complicated ulcer
10. Antiplatelet or NSAID with 2 of the following: concomitant systemic corticosteroids, age over 60 years, previous uncomplicated ulcer, concomitant NSAID, or antiplatelet/anticoagulant

The process of evaluating and stopping PPIs was voluntary. Housestaff were encouraged to evaluate PPIs when ordering admission medications and upon preparing exit prescriptions. This was an opt‐in intervention. Once a patient on a PPI was identified, typically on admission to the unit, the indication for use could then be evaluated using the online tool, which was accessible on the internet via a link on all unit computers (see Supporting Information, Appendix, in the online version of this article).

The Web‐based tool was designed to be simple and informative. Users of the tool input anonymous data including comorbidities (check boxes provided). The tool collected the indication for PPI use, with available options including: the consensus‐derived evidence‐based indications, no identified indication, or free text. This was done purposefully to remind the teams of the consensus indications, with the goal that in choosing no identified indication the resident would consider cessation of unnecessary PPIs. The final step in the tool, discharge plan, presented the option of stopping the PPI in the absence of a satisfactory indication. We hypothesized that selecting this option would serve as an informal commitment to discontinuing the PPI during the creation of the discharge prescription; however, the tool was not automatically linked to these prescriptions.

If a home prescription was discontinued, the patient was counselled by the treating team and provided with an educational letter (see Supporting Information, Appendix, in the online version of this article), which was fastened to their discharge summary and given to the patient for delivery to all of their usual outpatient physician(s).

The design of the online tool was such that residents were to evaluate PPI use that would continue postdischarge from the hospital, rather than PPI use limited to the period of hospitalization.

Data Collection and Statistical Analysis

Data on baseline demographics and the specific indications for PPI use were collected through clinician interaction with the online tool. The proportion of patients on a PPI was ascertained through a separate data extraction of electronic discharge prescriptions. These involved medication reconciliation for all outpatient medications including whether or not they were continued, modified, or stopped. Thus, we could determine at discharge whether outpatient PPIs were continued or stopped or if a new PPI was initiated.

The proportion of patients admitted from home already receiving a PPI, those who received a new prescription for a PPI at discharge, and those whose PPI was stopped during admission were compared before and after the intervention using segmented regression analysis of an interrupted time series (see Supporting Information, Appendix, in the online version of this article).[24]

Post Hoc Power Calculations

For the pre‐post comparisons, given the preintervention number of admissions, proportions of PPI use in the community, new PPI use, and PPI discontinuation rates we would have had an 80% power to detect changes of 8.5%, 5%, and 5.5%, respectively.

Ethics

The McGill University Health Centre research ethics board approved this study. Informed consent was waived as the intervention was deemed to be best practice, and data collected were anonymous. Clinical consent was obtained by the treating team for all care decisions.

Funding

This initiative was conducted without any funding.

RESULTS

During the preintervention period, 464 patients were admitted, of whom 209 (45%) were taking a PPI prior to admission. During their hospitalization, an additional 53 patients (21% of nonusers) were newly prescribed a PPI that was continued at discharge. During the intervention period, a total of 640 patients were admitted, of whom 281 (44%) were taking a PPI prior to admission. During their hospitalization, 60 patients (17% of nonusers) were newly prescribed a PPI that was continued at discharge. Neither the monthly proportions admitted on PPIs from prior to admission (level P=0.59, slope P=0.46) or those newly initiated on a PPI (level P=0.36, slope P=0.18) were significantly different before compared to after the intervention. However, there was both a clinically and statistically significant difference in the proportion of preadmission PPIs that were discontinued at hospital discharge from a monthly mean of 7.7% (or 16/209) before intervention to 18.5% (or 52/281) afterward (Figure 1; level P=0.03, slope P=0.48).

Figure 1
Cessation of proton pump inhibitor (PPI) at discharge by academic period (P).

During the intervention period, our teams prospectively captured PPI indications and patient comorbidities for 54% (152/281) of the patients admitted on a PPI using the online assessment tool. The baseline characteristics of the population in whom the online tool was applied are shown in Table 2. These patients had a mean age of 69.6 years, and 49% were male. Thirty‐two percent had diabetes, 20% had chronic renal insufficiency, and 13% had experienced a gastrointestinal hemorrhage within the 3 months prior to admission. It was frequent for PPI users to receive systemic antibiotics (44%) or to have diagnoses potentially associated with PPI use such as community‐acquired pneumonia (25%) or C difficile (11%).

Demographic Characteristics of 152 Audited Patients on PPIs
CharacteristicValue
  • NOTE: Abbreviations: ER, emergency room; GFR, glomerular filtration rate; GI, gastrointestinal; ICU, intensive care unit; NSAID, nonsteroidal anti‐inflammatory drug; PPI, proton pump inhibitor; SD, standard deviation.

Age, y, mean (SD)69.615.1
Male gender, N (%)75 (49)
Initiation of PPI, N (%) 
Prior to hospitalization127 (84)
During hospitalization10 (6)
In ICU7 (4)
In ER8 (5)
Comorbidities, N (%) 
Diabetes mellitus48 (32)
Chronic renal failure, GFR <4529 (20)
GI bleed in the last 3 months20 (13)
No comorbidities11 (7)
Medications, N (%) 
Current antiplatelet agent67 (44)
Current corticosteroid use40 (26)
Current therapeutic anticoagulation35 (23)
Current NSAID use13 (8.5)
Current bisphosphonate13 (8.5)
Potential contraindications to PPI, N (%) 
Current antibiotic therapy67 (44)
Pneumonia38 (25)
Clostridium difficile infection ever16 (11)
Clostridium difficile infection on present admission9 (6)

Fifty‐four percent (82/152) of patients in whom the online tool was applied had an evidence‐based indication (Table 3). The most common indication for PPI prescription was the receipt of antiplatelet/anticoagulant or nonsteroidal anti‐inflammatory drug with 2 other known risk factors for upper gastrointestinal bleeding (20%). In the remaining 46% (70/152) of patients, the prescription of a PPI was deemed nonevidence based. Of these, 34 (49%) had their PPI discontinued. When patients were approached to discontinue therapy, the rate of success was high, with only 2 refusals.

Indications for Proton Pump Inhibitor Prescriptions in 152 Audited Patients
IndicationsN (%)
  • NOTE: Abbreviations: GERD, gastroesophageal reflux disease; NSAID, nonsteroidal anti‐inflammatory drug.

  • Included: acetylsalicylic acid (aspirin) receipt without any other risk for bleeding, anemia (not iron deficiency), nonspecific abdominal pain.

Approved indications for therapy 
Antiplatelet or NSAID with 2 of the following: age >60 years, systemic corticosteroids, previous uncomplicated ulcer, NSAID, or antiplatelet/anticoagulant28 (20)
Gastric or duodenal ulcer within the past 3 months23 (15)
Antiplatelet therapy with anticoagulants17 (11)
GERD with exacerbations within the last 3 months17 (11)
Dual antiplatelet therapy7 (5)
Pathological hypersecretory conditions0
Helicobactor pylori eradication0
Total with consensus indications79 (54)
Other described indications for therapy 
No indication identified46 (30)
Othera22 (14)
Palliative patients GERD prophylaxis5 (3)
Total without consensus indications70 (46)

DISCUSSION

In this prospective intervention, 44% of patients admitted to an acute‐care medical ward were prescribed a PPI prior to their admission. In the subgroup of patients for whom the indication for PPI use was recorded through our online tool, less than half had an evidence‐based indication for ongoing therapy. Our intervention was successful in increasing the proportion of patients in whom preadmission PPI prescriptions were stopped at discharge from an average of 7.7% in the preintervention phase to 18.5% during the intervention. This intervention is novel in that we were able to reduce active community prescriptions for PPIs in patients without obvious indication by nearly 50%.

Our population's rates of PPI prescription were consistent with previous reports,[11, 12, 13, 15, 25, 26, 27, 28] and it is clear that many hospitalized patients continue their PPIs at discharge without clear indications. We propose that hospitalization can serve as an opportunity to reassess the necessity of continuous PPI use. Previous systematic attempts to reduce inappropriate PPI prescriptions in hospital have met with varied success. Several of these studies were unable to achieve a demonstrable effect.[23, 29, 30, 31] In contrast, Hamzat et al.[30] described a successful educational intervention targeting inpatients on a geriatric ward. A 4‐week educational strategy was employed, and they were able to discontinue PPIs in 10 of 60 (17%) patients without indication during a limited period of study. Another successful intervention by Gupta et al.[32] involved a before‐and‐after study combining a half‐hour physician education session with the introduction of a medication reconciliation tool. They showed a decrease in inappropriate discharge prescriptions of 50%. Not only did our study demonstrate an equally sizable reduction in inappropriate discharge prescriptions, but we also employed a more methodologically sound time‐series analysis to control for unmeasured contemporaneous factors such as rotating staff practices or monthly differences in patient composition. We demonstrated an immediate and sustained improvement in performance that lasted over 6 months. Furthermore, in contrast to other interventions, which addressed inappropriate inpatient use persisting on discharge, our intervention also addressed the appropriateness of PPI use that antedated hospitalization.

There are common themes to the successful programs. The more time spent educating and reminding the prescribing physicians, the more successful the intervention. Nonetheless, we believe our intervention is not onerous or overly time consuming. We performed a short presentation each month to educate rotating physicians, and the tool took less than 1 minute to complete once the information on PPI indication was available. Frequent education sessions may be initially necessary given the comfort that many physicians have developed in prescribing PPIs. A further prerequisite for success may be a familiarity with PPI indications and potential adverse effects. Without this, the intervention may not show a demonstrable effect, as was seen in a study of pulmonologists.[23] We hypothesize that some subspecialist physicians may not have the same appreciation of the adverse effects of PPIs nor the confidence to stop them when not indicated, as compared to general internists or hospitalists.

The proportion of patients with newly initiated PPIs at discharge decreased after the intervention, but this did not reach statistical significance. Our study's power may have precluded this. However, we had also previously put in place unpublished interventions to diminish inappropriate gastric prophylaxis in the hospital, which may have diminished the effect of this intervention.

Unfortunately, although we demonstrated a clinically significant effect on PPI exit prescription rates, we still found that nearly half of the patients who were evaluated using the online tool were discharged on PPIs despite our physicians' acknowledgment that they had no identifiable indication. It is possible that clinicians do not feel comfortable stopping these medications, owing to a fear that there is an indication that they are not aware of. In certain cases, it is possible that a reappraisal of the benefits, risks, and costs might reassure the clinician that they could safely stop the drug; however, therapeutic inertia is often hard to overcome.

Limitations

Our single‐center study occurred over a limited time period and examined a sample of patients that were assessed based on convenience. Other limitations included the uptake of the online tool, which was only 54% of patients on a PPI. In particular, few patients who were newly started on a PPI had the online tool applied. This is likely because the tool was filled out on a volunteer basis and was applied most routinely during the admission medication reconciliation process. There were a number of other reasons why the tool was underused, including having the inpatient teams responsible for the data collection despite preexisting demands on their time and the lack of data from patients who were admitted and discharged before a thorough review of the indication for PPI use could take place. However, despite the incomplete use of the online tool, the demographics of patients who were assessed are similar to our usual patient population. As such, we believe the data captured are representative. Furthermore, despite the tool being underused, there remained a clearly objectified reduction in PPI exit prescriptions that occurred immediately postintervention and persisted throughout the entire period of study. Although our teams were not universally using the Web‐tool, it was clear that they were influenced by the project and were stopping unnecessary therapy.

Additionally, the absence of postdischarge follow‐up is also an important limitation. We had originally planned to audit all patients whose PPIs were stopped at 3 months postdischarge but were not systematically able to do so. We did, however, obtain a 1‐time convenience sample interview midway through the intervention. At that time, of 18 patients interviewed, all but 1 remained off of their PPI at 3 months postdischarge. The 1 restart was for reflux symptoms without a preceding trial of lifestyle therapy or H2 blocker.

One final limitation of this study design is that the implementation portion of the intervention took place at the beginning of the academic year. Trainees at the beginning of the year might differ from trainees at the end of the year in that they are more receptive to an educational intervention and less firmly fixed in their practice patterns. If one is considering implementing a similar strategy in their academic institution, we recommend doing so at the start of the academic year to capture the interest of new trainees, maximize the intervention's effectiveness, and establish good habits early in training.

CONCLUSION

We have demonstrated that in medical inpatients, both PPI use and misuse remain common; however, with a combined educational and Web‐based QI intervention, we could successfully decrease inappropriate exit prescriptions. Hospitalization, particularly at academic centers, should serve as an important point of contact for residents in training and expert faculty physicians to reconsider and rationalize patient medications. We should take the opportunity to engender a culture of responsibility for all of the medications that we represcribe at discharge, including an appraisal of the relevant harms and benefits, particularly when a medication is potentially unnecessary. We ought to then communicate the rationale for any changes to our community partners to maintain continuity of care. In this way, hospitalists can help treat the prescription indigestion that has become a common affliction in modern medicine.

Disclosure

Nothing to report.

Files
References
  1. IMS Institute for Healthcare Informatics. Medicine Use and Shifting Costs of Healthcare. 2014. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Secure/IIHI_US_Use_of_Meds_for_2013.pdf. Accessed September 26, 2014.
  2. Johansen ME, Huerta TR, Richardson CR. National use of proton pump inhibitors from 2007 to 2011. JAMA Intern Med. 2014;174(11):18561858.
  3. Health Canada. Proton Pump Inhibitors (antacids): Possible Risk of Clostridium difficile‐Associated Diarrhea. 2012. Available at: http://www.healthycanadians.gc.ca/recall‐alert‐rappel‐avis/hc‐sc/2012/13651a‐eng.php. Accessed February 16, 2015.
  4. Health Canada. Proton Pump Inhibitors: Hypomagnesemia Accompanied by Hypocalcemia and Hypokalemia. 2011. Available at: http://www.hc‐sc.gc.ca/dhp‐mps/medeff/bulletin/carn‐bcei_v21n3‐eng.php#_Proton_pump_inhibitors. Accessed February 16, 2015.
  5. US Food and Drug Administration. FDA Drug Safety Communication: Possible Increased Risk of Fractures of the Hip, Wrist, and Spine With the Use of Proton Pump Inhibitors. 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed February 15, 2015.
  6. US Food and Drug Administration. FDA Drug Safety Communication: Clostridium difficile‐Associated Diarrhea Can Be Associated With Stomach Acid Drugs Known as Proton Pump Inhibitors (PPIs). 2012. Available at: http://www.fda.gov/drugs/drugsafety/ucm290510.htm. Accessed February 15, 2015.
  7. Johnstone J, Nerenberg K, Loeb M. Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):11651177.
  8. Maggio M, Corsonello A, Ceda GP, et al. Proton pump inhibitors and risk of 1‐year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173(7):518523.
  9. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid‐suppressive medication use and the risk for hospital‐acquired pneumonia. JAMA. 2009;301(20):21202128.
  10. Corsonello A, Maggio M, Fusco S, et al. Proton pump inhibitors and functional decline in older adults discharged from acute care hospitals. J Am Geriatr Soc. 2014;62(6):11101115.
  11. Albugeaey M, Alfaraj N, Garb J, Seiler A, Lagu T. Do hospitalists overuse proton pump inhibitors? Data from a contemporary cohort. J Hosp Med. 2014;9(11):731733.
  12. Reid M, Keniston A, Heller JC, Miller M, Medvedev S, Albert RK. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7(5):421425.
  13. Ladd AM, Panagopoulos G, Cohen J, Mar N, Graham R. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347(6):446451.
  14. Zink DA, Pohlman M, Barnes M, Cannon ME. Long‐term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21(10):12031209.
  15. Grant K, Al‐Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28(4):189193.
  16. Breu AC, Allen‐Dicker J, Mueller S, Palamara K, Hinami K, Herzig SJ. Hospitalist and primary care physician perspectives on medication management of chronic conditions for hospitalized patients. J Hosp Med. 2014;9(5):303309.
  17. Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med. 1995;332(3):139142.
  18. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343(5):310316.
  19. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long‐term low‐dose aspirin use. N Engl J Med. 2002;346(26):20332038.
  20. Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):18081825.
  21. Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID‐related ulcer complications. Am J Gastroenterol. 2009;104(3):728738.
  22. Rostom A, Moayyedi P, Hunt R, Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29(5):481496.
  23. van Vliet EP, Steyerberg EW, Otten HJ, et al., The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards. Aliment Pharmacol Ther. 2009;29(2):213221.
  24. Wagner AK, Soumerai SB, Zhang F, Ross‐Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299309.
  25. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid‐suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95(11):31183122.
  26. Mat Saad AZ, Collins N, Lobo MM, O'Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59(1):3134.
  27. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25(5):333340.
  28. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro‐esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205210.
  29. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):6668.
  30. Hamzat H, Sun H, Ford JC, Macleod J, Soiza RL, Mangoni AA. Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. Drugs Aging. 2012;29(8):681690.
  31. Chui D, Young F, Tejani AM, Dillon EC. Impact of academic detailing on proton pump inhibitor prescribing behaviour in a community hospital. Can Pharm J (Ott). 2011;144(2):6671.
  32. Gupta R, Marshall J, Munoz JC, Kottoor R, Jamal MM, Vega KJ. Decreased acid suppression therapy overuse after education and medication reconciliation. Int J Clin Pract. 2013;67(1):6065.
Article PDF
Issue
Journal of Hospital Medicine - 10(5)
Publications
Page Number
281-286
Sections
Files
Files
Article PDF
Article PDF

In 2013, there were more than 15 million Americans receiving proton pump inhibitors (PPIs),[1] with an associated drug cost of nearly $79 billion between 2007 and 2011.2 PPI use is reaching epidemic proportions, likely due to the medicalization of gastrointestinal symptoms coupled with pervasive marketing and academic detailing being performed by the pharmaceutical industry.

Although PPIs are generally considered safe, they are not as innocuous as many physicians believe. In 2011 and 2012, the US Food and Drug Administration and Health Canada, respectively, issued safety advisories regarding the use of these medications related to Clostridium difficile, fracture risk, and electrolyte derangement.[3, 4, 5, 6] There have also been numerous other harmful associations reported,[7, 8, 9, 10] suggesting it would be prudent to follow Health Canada's advice that: PPIs should be prescribed at the lowest dose and shortest duration of therapy appropriate to the condition being treated.[4] In many cases this implies stopping the PPI after an appropriate duration of therapy or attempting nonpharmacological or H2‐blocker therapy instead.

Nevertheless, despite numerous cautionary publications, PPI use for nonevidence‐based indications remains common. Because they are generally thought of as outpatient medications, PPIs are frequently continued in hospitalized patients, and inappropriate outpatient therapy is rarely addressed.[11, 12, 13] Likewise, inappropriate de novo use can also be observed during hospitalization and may continue on discharge.[13, 14, 15] Hospitalization may consequently present an opportunity to employ meaningful interventions targeting outpatient medication use.[16] We developed an opportune inpatient intervention targeting inappropriate PPI therapy.

Our study had 2 aims: first, to determine the magnitude of the problem in a contemporary Canadian medical inpatient population, and second, we sought to leverage the inpatient admission as an opportunity to promote change when the patient returned to the community through the application of an educational and web‐based quality‐improvement (QI) intervention.

METHODS

Patient Inclusion

Between January 2012 and December 2012, we included all consecutively admitted patients on our 46‐bed general medical clinical teaching unit belonging to a 417‐bed tertiary care teaching hospital in Montreal, Canada. There were no exclusion criteria. This time period was divided into 2 blocks: the preintervention control period from January 1 to June 3 and the intervention period from June 4 to December 16.

Intervention and Implementation Strategy

At the start of each academic period, we presented a 20‐minute information session on the benefits and harms of PPI use (see Supporting Information, Appendix, in the online version of this article). The unit's medical residents and faculty attended these rounds. The presentation described the project, consensus‐derived indications for PPI use, and potential adverse events attributable to PPIs (see Table 1 for indications based on internal consensus and similar studies[17, 18, 19, 20, 21, 22, 23]). All other indications were considered nonevidence based. At the end of the month, teams were given feedback on indications they provided using the Web tool and the proportion of patients they discharged on a PPI with and without indication.

Consensus Indications for Proton Pump Inhibitors
  • NOTE: Abbreviations: NSAID, nonsteroidal anti‐inflammatory drug.

1. Gastric or duodenal ulcer within the past 3 months
2. Pathological hypersecretory conditions
3. Gastroesophageal reflux disease with exacerbations within the last 3 months not responsive to H2 blockers and nonpharmacologic techniques
4. Erosive esophagitis
5. Recurring symptoms recently associated with severe indigestion within the last 3 months not responsive to H2 blocker or nonpharmacologic techniques
6. Helicobacter pylori eradication
7. Dual antiplatelet therapy
8. Antiplatelet therapy with anticoagulants
9. Antiplatelet or anticoagulant therapy with history of previous complicated ulcer
10. Antiplatelet or NSAID with 2 of the following: concomitant systemic corticosteroids, age over 60 years, previous uncomplicated ulcer, concomitant NSAID, or antiplatelet/anticoagulant

The process of evaluating and stopping PPIs was voluntary. Housestaff were encouraged to evaluate PPIs when ordering admission medications and upon preparing exit prescriptions. This was an opt‐in intervention. Once a patient on a PPI was identified, typically on admission to the unit, the indication for use could then be evaluated using the online tool, which was accessible on the internet via a link on all unit computers (see Supporting Information, Appendix, in the online version of this article).

The Web‐based tool was designed to be simple and informative. Users of the tool input anonymous data including comorbidities (check boxes provided). The tool collected the indication for PPI use, with available options including: the consensus‐derived evidence‐based indications, no identified indication, or free text. This was done purposefully to remind the teams of the consensus indications, with the goal that in choosing no identified indication the resident would consider cessation of unnecessary PPIs. The final step in the tool, discharge plan, presented the option of stopping the PPI in the absence of a satisfactory indication. We hypothesized that selecting this option would serve as an informal commitment to discontinuing the PPI during the creation of the discharge prescription; however, the tool was not automatically linked to these prescriptions.

If a home prescription was discontinued, the patient was counselled by the treating team and provided with an educational letter (see Supporting Information, Appendix, in the online version of this article), which was fastened to their discharge summary and given to the patient for delivery to all of their usual outpatient physician(s).

The design of the online tool was such that residents were to evaluate PPI use that would continue postdischarge from the hospital, rather than PPI use limited to the period of hospitalization.

Data Collection and Statistical Analysis

Data on baseline demographics and the specific indications for PPI use were collected through clinician interaction with the online tool. The proportion of patients on a PPI was ascertained through a separate data extraction of electronic discharge prescriptions. These involved medication reconciliation for all outpatient medications including whether or not they were continued, modified, or stopped. Thus, we could determine at discharge whether outpatient PPIs were continued or stopped or if a new PPI was initiated.

The proportion of patients admitted from home already receiving a PPI, those who received a new prescription for a PPI at discharge, and those whose PPI was stopped during admission were compared before and after the intervention using segmented regression analysis of an interrupted time series (see Supporting Information, Appendix, in the online version of this article).[24]

Post Hoc Power Calculations

For the pre‐post comparisons, given the preintervention number of admissions, proportions of PPI use in the community, new PPI use, and PPI discontinuation rates we would have had an 80% power to detect changes of 8.5%, 5%, and 5.5%, respectively.

Ethics

The McGill University Health Centre research ethics board approved this study. Informed consent was waived as the intervention was deemed to be best practice, and data collected were anonymous. Clinical consent was obtained by the treating team for all care decisions.

Funding

This initiative was conducted without any funding.

RESULTS

During the preintervention period, 464 patients were admitted, of whom 209 (45%) were taking a PPI prior to admission. During their hospitalization, an additional 53 patients (21% of nonusers) were newly prescribed a PPI that was continued at discharge. During the intervention period, a total of 640 patients were admitted, of whom 281 (44%) were taking a PPI prior to admission. During their hospitalization, 60 patients (17% of nonusers) were newly prescribed a PPI that was continued at discharge. Neither the monthly proportions admitted on PPIs from prior to admission (level P=0.59, slope P=0.46) or those newly initiated on a PPI (level P=0.36, slope P=0.18) were significantly different before compared to after the intervention. However, there was both a clinically and statistically significant difference in the proportion of preadmission PPIs that were discontinued at hospital discharge from a monthly mean of 7.7% (or 16/209) before intervention to 18.5% (or 52/281) afterward (Figure 1; level P=0.03, slope P=0.48).

Figure 1
Cessation of proton pump inhibitor (PPI) at discharge by academic period (P).

During the intervention period, our teams prospectively captured PPI indications and patient comorbidities for 54% (152/281) of the patients admitted on a PPI using the online assessment tool. The baseline characteristics of the population in whom the online tool was applied are shown in Table 2. These patients had a mean age of 69.6 years, and 49% were male. Thirty‐two percent had diabetes, 20% had chronic renal insufficiency, and 13% had experienced a gastrointestinal hemorrhage within the 3 months prior to admission. It was frequent for PPI users to receive systemic antibiotics (44%) or to have diagnoses potentially associated with PPI use such as community‐acquired pneumonia (25%) or C difficile (11%).

Demographic Characteristics of 152 Audited Patients on PPIs
CharacteristicValue
  • NOTE: Abbreviations: ER, emergency room; GFR, glomerular filtration rate; GI, gastrointestinal; ICU, intensive care unit; NSAID, nonsteroidal anti‐inflammatory drug; PPI, proton pump inhibitor; SD, standard deviation.

Age, y, mean (SD)69.615.1
Male gender, N (%)75 (49)
Initiation of PPI, N (%) 
Prior to hospitalization127 (84)
During hospitalization10 (6)
In ICU7 (4)
In ER8 (5)
Comorbidities, N (%) 
Diabetes mellitus48 (32)
Chronic renal failure, GFR <4529 (20)
GI bleed in the last 3 months20 (13)
No comorbidities11 (7)
Medications, N (%) 
Current antiplatelet agent67 (44)
Current corticosteroid use40 (26)
Current therapeutic anticoagulation35 (23)
Current NSAID use13 (8.5)
Current bisphosphonate13 (8.5)
Potential contraindications to PPI, N (%) 
Current antibiotic therapy67 (44)
Pneumonia38 (25)
Clostridium difficile infection ever16 (11)
Clostridium difficile infection on present admission9 (6)

Fifty‐four percent (82/152) of patients in whom the online tool was applied had an evidence‐based indication (Table 3). The most common indication for PPI prescription was the receipt of antiplatelet/anticoagulant or nonsteroidal anti‐inflammatory drug with 2 other known risk factors for upper gastrointestinal bleeding (20%). In the remaining 46% (70/152) of patients, the prescription of a PPI was deemed nonevidence based. Of these, 34 (49%) had their PPI discontinued. When patients were approached to discontinue therapy, the rate of success was high, with only 2 refusals.

Indications for Proton Pump Inhibitor Prescriptions in 152 Audited Patients
IndicationsN (%)
  • NOTE: Abbreviations: GERD, gastroesophageal reflux disease; NSAID, nonsteroidal anti‐inflammatory drug.

  • Included: acetylsalicylic acid (aspirin) receipt without any other risk for bleeding, anemia (not iron deficiency), nonspecific abdominal pain.

Approved indications for therapy 
Antiplatelet or NSAID with 2 of the following: age >60 years, systemic corticosteroids, previous uncomplicated ulcer, NSAID, or antiplatelet/anticoagulant28 (20)
Gastric or duodenal ulcer within the past 3 months23 (15)
Antiplatelet therapy with anticoagulants17 (11)
GERD with exacerbations within the last 3 months17 (11)
Dual antiplatelet therapy7 (5)
Pathological hypersecretory conditions0
Helicobactor pylori eradication0
Total with consensus indications79 (54)
Other described indications for therapy 
No indication identified46 (30)
Othera22 (14)
Palliative patients GERD prophylaxis5 (3)
Total without consensus indications70 (46)

DISCUSSION

In this prospective intervention, 44% of patients admitted to an acute‐care medical ward were prescribed a PPI prior to their admission. In the subgroup of patients for whom the indication for PPI use was recorded through our online tool, less than half had an evidence‐based indication for ongoing therapy. Our intervention was successful in increasing the proportion of patients in whom preadmission PPI prescriptions were stopped at discharge from an average of 7.7% in the preintervention phase to 18.5% during the intervention. This intervention is novel in that we were able to reduce active community prescriptions for PPIs in patients without obvious indication by nearly 50%.

Our population's rates of PPI prescription were consistent with previous reports,[11, 12, 13, 15, 25, 26, 27, 28] and it is clear that many hospitalized patients continue their PPIs at discharge without clear indications. We propose that hospitalization can serve as an opportunity to reassess the necessity of continuous PPI use. Previous systematic attempts to reduce inappropriate PPI prescriptions in hospital have met with varied success. Several of these studies were unable to achieve a demonstrable effect.[23, 29, 30, 31] In contrast, Hamzat et al.[30] described a successful educational intervention targeting inpatients on a geriatric ward. A 4‐week educational strategy was employed, and they were able to discontinue PPIs in 10 of 60 (17%) patients without indication during a limited period of study. Another successful intervention by Gupta et al.[32] involved a before‐and‐after study combining a half‐hour physician education session with the introduction of a medication reconciliation tool. They showed a decrease in inappropriate discharge prescriptions of 50%. Not only did our study demonstrate an equally sizable reduction in inappropriate discharge prescriptions, but we also employed a more methodologically sound time‐series analysis to control for unmeasured contemporaneous factors such as rotating staff practices or monthly differences in patient composition. We demonstrated an immediate and sustained improvement in performance that lasted over 6 months. Furthermore, in contrast to other interventions, which addressed inappropriate inpatient use persisting on discharge, our intervention also addressed the appropriateness of PPI use that antedated hospitalization.

There are common themes to the successful programs. The more time spent educating and reminding the prescribing physicians, the more successful the intervention. Nonetheless, we believe our intervention is not onerous or overly time consuming. We performed a short presentation each month to educate rotating physicians, and the tool took less than 1 minute to complete once the information on PPI indication was available. Frequent education sessions may be initially necessary given the comfort that many physicians have developed in prescribing PPIs. A further prerequisite for success may be a familiarity with PPI indications and potential adverse effects. Without this, the intervention may not show a demonstrable effect, as was seen in a study of pulmonologists.[23] We hypothesize that some subspecialist physicians may not have the same appreciation of the adverse effects of PPIs nor the confidence to stop them when not indicated, as compared to general internists or hospitalists.

The proportion of patients with newly initiated PPIs at discharge decreased after the intervention, but this did not reach statistical significance. Our study's power may have precluded this. However, we had also previously put in place unpublished interventions to diminish inappropriate gastric prophylaxis in the hospital, which may have diminished the effect of this intervention.

Unfortunately, although we demonstrated a clinically significant effect on PPI exit prescription rates, we still found that nearly half of the patients who were evaluated using the online tool were discharged on PPIs despite our physicians' acknowledgment that they had no identifiable indication. It is possible that clinicians do not feel comfortable stopping these medications, owing to a fear that there is an indication that they are not aware of. In certain cases, it is possible that a reappraisal of the benefits, risks, and costs might reassure the clinician that they could safely stop the drug; however, therapeutic inertia is often hard to overcome.

Limitations

Our single‐center study occurred over a limited time period and examined a sample of patients that were assessed based on convenience. Other limitations included the uptake of the online tool, which was only 54% of patients on a PPI. In particular, few patients who were newly started on a PPI had the online tool applied. This is likely because the tool was filled out on a volunteer basis and was applied most routinely during the admission medication reconciliation process. There were a number of other reasons why the tool was underused, including having the inpatient teams responsible for the data collection despite preexisting demands on their time and the lack of data from patients who were admitted and discharged before a thorough review of the indication for PPI use could take place. However, despite the incomplete use of the online tool, the demographics of patients who were assessed are similar to our usual patient population. As such, we believe the data captured are representative. Furthermore, despite the tool being underused, there remained a clearly objectified reduction in PPI exit prescriptions that occurred immediately postintervention and persisted throughout the entire period of study. Although our teams were not universally using the Web‐tool, it was clear that they were influenced by the project and were stopping unnecessary therapy.

Additionally, the absence of postdischarge follow‐up is also an important limitation. We had originally planned to audit all patients whose PPIs were stopped at 3 months postdischarge but were not systematically able to do so. We did, however, obtain a 1‐time convenience sample interview midway through the intervention. At that time, of 18 patients interviewed, all but 1 remained off of their PPI at 3 months postdischarge. The 1 restart was for reflux symptoms without a preceding trial of lifestyle therapy or H2 blocker.

One final limitation of this study design is that the implementation portion of the intervention took place at the beginning of the academic year. Trainees at the beginning of the year might differ from trainees at the end of the year in that they are more receptive to an educational intervention and less firmly fixed in their practice patterns. If one is considering implementing a similar strategy in their academic institution, we recommend doing so at the start of the academic year to capture the interest of new trainees, maximize the intervention's effectiveness, and establish good habits early in training.

CONCLUSION

We have demonstrated that in medical inpatients, both PPI use and misuse remain common; however, with a combined educational and Web‐based QI intervention, we could successfully decrease inappropriate exit prescriptions. Hospitalization, particularly at academic centers, should serve as an important point of contact for residents in training and expert faculty physicians to reconsider and rationalize patient medications. We should take the opportunity to engender a culture of responsibility for all of the medications that we represcribe at discharge, including an appraisal of the relevant harms and benefits, particularly when a medication is potentially unnecessary. We ought to then communicate the rationale for any changes to our community partners to maintain continuity of care. In this way, hospitalists can help treat the prescription indigestion that has become a common affliction in modern medicine.

Disclosure

Nothing to report.

In 2013, there were more than 15 million Americans receiving proton pump inhibitors (PPIs),[1] with an associated drug cost of nearly $79 billion between 2007 and 2011.2 PPI use is reaching epidemic proportions, likely due to the medicalization of gastrointestinal symptoms coupled with pervasive marketing and academic detailing being performed by the pharmaceutical industry.

Although PPIs are generally considered safe, they are not as innocuous as many physicians believe. In 2011 and 2012, the US Food and Drug Administration and Health Canada, respectively, issued safety advisories regarding the use of these medications related to Clostridium difficile, fracture risk, and electrolyte derangement.[3, 4, 5, 6] There have also been numerous other harmful associations reported,[7, 8, 9, 10] suggesting it would be prudent to follow Health Canada's advice that: PPIs should be prescribed at the lowest dose and shortest duration of therapy appropriate to the condition being treated.[4] In many cases this implies stopping the PPI after an appropriate duration of therapy or attempting nonpharmacological or H2‐blocker therapy instead.

Nevertheless, despite numerous cautionary publications, PPI use for nonevidence‐based indications remains common. Because they are generally thought of as outpatient medications, PPIs are frequently continued in hospitalized patients, and inappropriate outpatient therapy is rarely addressed.[11, 12, 13] Likewise, inappropriate de novo use can also be observed during hospitalization and may continue on discharge.[13, 14, 15] Hospitalization may consequently present an opportunity to employ meaningful interventions targeting outpatient medication use.[16] We developed an opportune inpatient intervention targeting inappropriate PPI therapy.

Our study had 2 aims: first, to determine the magnitude of the problem in a contemporary Canadian medical inpatient population, and second, we sought to leverage the inpatient admission as an opportunity to promote change when the patient returned to the community through the application of an educational and web‐based quality‐improvement (QI) intervention.

METHODS

Patient Inclusion

Between January 2012 and December 2012, we included all consecutively admitted patients on our 46‐bed general medical clinical teaching unit belonging to a 417‐bed tertiary care teaching hospital in Montreal, Canada. There were no exclusion criteria. This time period was divided into 2 blocks: the preintervention control period from January 1 to June 3 and the intervention period from June 4 to December 16.

Intervention and Implementation Strategy

At the start of each academic period, we presented a 20‐minute information session on the benefits and harms of PPI use (see Supporting Information, Appendix, in the online version of this article). The unit's medical residents and faculty attended these rounds. The presentation described the project, consensus‐derived indications for PPI use, and potential adverse events attributable to PPIs (see Table 1 for indications based on internal consensus and similar studies[17, 18, 19, 20, 21, 22, 23]). All other indications were considered nonevidence based. At the end of the month, teams were given feedback on indications they provided using the Web tool and the proportion of patients they discharged on a PPI with and without indication.

Consensus Indications for Proton Pump Inhibitors
  • NOTE: Abbreviations: NSAID, nonsteroidal anti‐inflammatory drug.

1. Gastric or duodenal ulcer within the past 3 months
2. Pathological hypersecretory conditions
3. Gastroesophageal reflux disease with exacerbations within the last 3 months not responsive to H2 blockers and nonpharmacologic techniques
4. Erosive esophagitis
5. Recurring symptoms recently associated with severe indigestion within the last 3 months not responsive to H2 blocker or nonpharmacologic techniques
6. Helicobacter pylori eradication
7. Dual antiplatelet therapy
8. Antiplatelet therapy with anticoagulants
9. Antiplatelet or anticoagulant therapy with history of previous complicated ulcer
10. Antiplatelet or NSAID with 2 of the following: concomitant systemic corticosteroids, age over 60 years, previous uncomplicated ulcer, concomitant NSAID, or antiplatelet/anticoagulant

The process of evaluating and stopping PPIs was voluntary. Housestaff were encouraged to evaluate PPIs when ordering admission medications and upon preparing exit prescriptions. This was an opt‐in intervention. Once a patient on a PPI was identified, typically on admission to the unit, the indication for use could then be evaluated using the online tool, which was accessible on the internet via a link on all unit computers (see Supporting Information, Appendix, in the online version of this article).

The Web‐based tool was designed to be simple and informative. Users of the tool input anonymous data including comorbidities (check boxes provided). The tool collected the indication for PPI use, with available options including: the consensus‐derived evidence‐based indications, no identified indication, or free text. This was done purposefully to remind the teams of the consensus indications, with the goal that in choosing no identified indication the resident would consider cessation of unnecessary PPIs. The final step in the tool, discharge plan, presented the option of stopping the PPI in the absence of a satisfactory indication. We hypothesized that selecting this option would serve as an informal commitment to discontinuing the PPI during the creation of the discharge prescription; however, the tool was not automatically linked to these prescriptions.

If a home prescription was discontinued, the patient was counselled by the treating team and provided with an educational letter (see Supporting Information, Appendix, in the online version of this article), which was fastened to their discharge summary and given to the patient for delivery to all of their usual outpatient physician(s).

The design of the online tool was such that residents were to evaluate PPI use that would continue postdischarge from the hospital, rather than PPI use limited to the period of hospitalization.

Data Collection and Statistical Analysis

Data on baseline demographics and the specific indications for PPI use were collected through clinician interaction with the online tool. The proportion of patients on a PPI was ascertained through a separate data extraction of electronic discharge prescriptions. These involved medication reconciliation for all outpatient medications including whether or not they were continued, modified, or stopped. Thus, we could determine at discharge whether outpatient PPIs were continued or stopped or if a new PPI was initiated.

The proportion of patients admitted from home already receiving a PPI, those who received a new prescription for a PPI at discharge, and those whose PPI was stopped during admission were compared before and after the intervention using segmented regression analysis of an interrupted time series (see Supporting Information, Appendix, in the online version of this article).[24]

Post Hoc Power Calculations

For the pre‐post comparisons, given the preintervention number of admissions, proportions of PPI use in the community, new PPI use, and PPI discontinuation rates we would have had an 80% power to detect changes of 8.5%, 5%, and 5.5%, respectively.

Ethics

The McGill University Health Centre research ethics board approved this study. Informed consent was waived as the intervention was deemed to be best practice, and data collected were anonymous. Clinical consent was obtained by the treating team for all care decisions.

Funding

This initiative was conducted without any funding.

RESULTS

During the preintervention period, 464 patients were admitted, of whom 209 (45%) were taking a PPI prior to admission. During their hospitalization, an additional 53 patients (21% of nonusers) were newly prescribed a PPI that was continued at discharge. During the intervention period, a total of 640 patients were admitted, of whom 281 (44%) were taking a PPI prior to admission. During their hospitalization, 60 patients (17% of nonusers) were newly prescribed a PPI that was continued at discharge. Neither the monthly proportions admitted on PPIs from prior to admission (level P=0.59, slope P=0.46) or those newly initiated on a PPI (level P=0.36, slope P=0.18) were significantly different before compared to after the intervention. However, there was both a clinically and statistically significant difference in the proportion of preadmission PPIs that were discontinued at hospital discharge from a monthly mean of 7.7% (or 16/209) before intervention to 18.5% (or 52/281) afterward (Figure 1; level P=0.03, slope P=0.48).

Figure 1
Cessation of proton pump inhibitor (PPI) at discharge by academic period (P).

During the intervention period, our teams prospectively captured PPI indications and patient comorbidities for 54% (152/281) of the patients admitted on a PPI using the online assessment tool. The baseline characteristics of the population in whom the online tool was applied are shown in Table 2. These patients had a mean age of 69.6 years, and 49% were male. Thirty‐two percent had diabetes, 20% had chronic renal insufficiency, and 13% had experienced a gastrointestinal hemorrhage within the 3 months prior to admission. It was frequent for PPI users to receive systemic antibiotics (44%) or to have diagnoses potentially associated with PPI use such as community‐acquired pneumonia (25%) or C difficile (11%).

Demographic Characteristics of 152 Audited Patients on PPIs
CharacteristicValue
  • NOTE: Abbreviations: ER, emergency room; GFR, glomerular filtration rate; GI, gastrointestinal; ICU, intensive care unit; NSAID, nonsteroidal anti‐inflammatory drug; PPI, proton pump inhibitor; SD, standard deviation.

Age, y, mean (SD)69.615.1
Male gender, N (%)75 (49)
Initiation of PPI, N (%) 
Prior to hospitalization127 (84)
During hospitalization10 (6)
In ICU7 (4)
In ER8 (5)
Comorbidities, N (%) 
Diabetes mellitus48 (32)
Chronic renal failure, GFR <4529 (20)
GI bleed in the last 3 months20 (13)
No comorbidities11 (7)
Medications, N (%) 
Current antiplatelet agent67 (44)
Current corticosteroid use40 (26)
Current therapeutic anticoagulation35 (23)
Current NSAID use13 (8.5)
Current bisphosphonate13 (8.5)
Potential contraindications to PPI, N (%) 
Current antibiotic therapy67 (44)
Pneumonia38 (25)
Clostridium difficile infection ever16 (11)
Clostridium difficile infection on present admission9 (6)

Fifty‐four percent (82/152) of patients in whom the online tool was applied had an evidence‐based indication (Table 3). The most common indication for PPI prescription was the receipt of antiplatelet/anticoagulant or nonsteroidal anti‐inflammatory drug with 2 other known risk factors for upper gastrointestinal bleeding (20%). In the remaining 46% (70/152) of patients, the prescription of a PPI was deemed nonevidence based. Of these, 34 (49%) had their PPI discontinued. When patients were approached to discontinue therapy, the rate of success was high, with only 2 refusals.

Indications for Proton Pump Inhibitor Prescriptions in 152 Audited Patients
IndicationsN (%)
  • NOTE: Abbreviations: GERD, gastroesophageal reflux disease; NSAID, nonsteroidal anti‐inflammatory drug.

  • Included: acetylsalicylic acid (aspirin) receipt without any other risk for bleeding, anemia (not iron deficiency), nonspecific abdominal pain.

Approved indications for therapy 
Antiplatelet or NSAID with 2 of the following: age >60 years, systemic corticosteroids, previous uncomplicated ulcer, NSAID, or antiplatelet/anticoagulant28 (20)
Gastric or duodenal ulcer within the past 3 months23 (15)
Antiplatelet therapy with anticoagulants17 (11)
GERD with exacerbations within the last 3 months17 (11)
Dual antiplatelet therapy7 (5)
Pathological hypersecretory conditions0
Helicobactor pylori eradication0
Total with consensus indications79 (54)
Other described indications for therapy 
No indication identified46 (30)
Othera22 (14)
Palliative patients GERD prophylaxis5 (3)
Total without consensus indications70 (46)

DISCUSSION

In this prospective intervention, 44% of patients admitted to an acute‐care medical ward were prescribed a PPI prior to their admission. In the subgroup of patients for whom the indication for PPI use was recorded through our online tool, less than half had an evidence‐based indication for ongoing therapy. Our intervention was successful in increasing the proportion of patients in whom preadmission PPI prescriptions were stopped at discharge from an average of 7.7% in the preintervention phase to 18.5% during the intervention. This intervention is novel in that we were able to reduce active community prescriptions for PPIs in patients without obvious indication by nearly 50%.

Our population's rates of PPI prescription were consistent with previous reports,[11, 12, 13, 15, 25, 26, 27, 28] and it is clear that many hospitalized patients continue their PPIs at discharge without clear indications. We propose that hospitalization can serve as an opportunity to reassess the necessity of continuous PPI use. Previous systematic attempts to reduce inappropriate PPI prescriptions in hospital have met with varied success. Several of these studies were unable to achieve a demonstrable effect.[23, 29, 30, 31] In contrast, Hamzat et al.[30] described a successful educational intervention targeting inpatients on a geriatric ward. A 4‐week educational strategy was employed, and they were able to discontinue PPIs in 10 of 60 (17%) patients without indication during a limited period of study. Another successful intervention by Gupta et al.[32] involved a before‐and‐after study combining a half‐hour physician education session with the introduction of a medication reconciliation tool. They showed a decrease in inappropriate discharge prescriptions of 50%. Not only did our study demonstrate an equally sizable reduction in inappropriate discharge prescriptions, but we also employed a more methodologically sound time‐series analysis to control for unmeasured contemporaneous factors such as rotating staff practices or monthly differences in patient composition. We demonstrated an immediate and sustained improvement in performance that lasted over 6 months. Furthermore, in contrast to other interventions, which addressed inappropriate inpatient use persisting on discharge, our intervention also addressed the appropriateness of PPI use that antedated hospitalization.

There are common themes to the successful programs. The more time spent educating and reminding the prescribing physicians, the more successful the intervention. Nonetheless, we believe our intervention is not onerous or overly time consuming. We performed a short presentation each month to educate rotating physicians, and the tool took less than 1 minute to complete once the information on PPI indication was available. Frequent education sessions may be initially necessary given the comfort that many physicians have developed in prescribing PPIs. A further prerequisite for success may be a familiarity with PPI indications and potential adverse effects. Without this, the intervention may not show a demonstrable effect, as was seen in a study of pulmonologists.[23] We hypothesize that some subspecialist physicians may not have the same appreciation of the adverse effects of PPIs nor the confidence to stop them when not indicated, as compared to general internists or hospitalists.

The proportion of patients with newly initiated PPIs at discharge decreased after the intervention, but this did not reach statistical significance. Our study's power may have precluded this. However, we had also previously put in place unpublished interventions to diminish inappropriate gastric prophylaxis in the hospital, which may have diminished the effect of this intervention.

Unfortunately, although we demonstrated a clinically significant effect on PPI exit prescription rates, we still found that nearly half of the patients who were evaluated using the online tool were discharged on PPIs despite our physicians' acknowledgment that they had no identifiable indication. It is possible that clinicians do not feel comfortable stopping these medications, owing to a fear that there is an indication that they are not aware of. In certain cases, it is possible that a reappraisal of the benefits, risks, and costs might reassure the clinician that they could safely stop the drug; however, therapeutic inertia is often hard to overcome.

Limitations

Our single‐center study occurred over a limited time period and examined a sample of patients that were assessed based on convenience. Other limitations included the uptake of the online tool, which was only 54% of patients on a PPI. In particular, few patients who were newly started on a PPI had the online tool applied. This is likely because the tool was filled out on a volunteer basis and was applied most routinely during the admission medication reconciliation process. There were a number of other reasons why the tool was underused, including having the inpatient teams responsible for the data collection despite preexisting demands on their time and the lack of data from patients who were admitted and discharged before a thorough review of the indication for PPI use could take place. However, despite the incomplete use of the online tool, the demographics of patients who were assessed are similar to our usual patient population. As such, we believe the data captured are representative. Furthermore, despite the tool being underused, there remained a clearly objectified reduction in PPI exit prescriptions that occurred immediately postintervention and persisted throughout the entire period of study. Although our teams were not universally using the Web‐tool, it was clear that they were influenced by the project and were stopping unnecessary therapy.

Additionally, the absence of postdischarge follow‐up is also an important limitation. We had originally planned to audit all patients whose PPIs were stopped at 3 months postdischarge but were not systematically able to do so. We did, however, obtain a 1‐time convenience sample interview midway through the intervention. At that time, of 18 patients interviewed, all but 1 remained off of their PPI at 3 months postdischarge. The 1 restart was for reflux symptoms without a preceding trial of lifestyle therapy or H2 blocker.

One final limitation of this study design is that the implementation portion of the intervention took place at the beginning of the academic year. Trainees at the beginning of the year might differ from trainees at the end of the year in that they are more receptive to an educational intervention and less firmly fixed in their practice patterns. If one is considering implementing a similar strategy in their academic institution, we recommend doing so at the start of the academic year to capture the interest of new trainees, maximize the intervention's effectiveness, and establish good habits early in training.

CONCLUSION

We have demonstrated that in medical inpatients, both PPI use and misuse remain common; however, with a combined educational and Web‐based QI intervention, we could successfully decrease inappropriate exit prescriptions. Hospitalization, particularly at academic centers, should serve as an important point of contact for residents in training and expert faculty physicians to reconsider and rationalize patient medications. We should take the opportunity to engender a culture of responsibility for all of the medications that we represcribe at discharge, including an appraisal of the relevant harms and benefits, particularly when a medication is potentially unnecessary. We ought to then communicate the rationale for any changes to our community partners to maintain continuity of care. In this way, hospitalists can help treat the prescription indigestion that has become a common affliction in modern medicine.

Disclosure

Nothing to report.

References
  1. IMS Institute for Healthcare Informatics. Medicine Use and Shifting Costs of Healthcare. 2014. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Secure/IIHI_US_Use_of_Meds_for_2013.pdf. Accessed September 26, 2014.
  2. Johansen ME, Huerta TR, Richardson CR. National use of proton pump inhibitors from 2007 to 2011. JAMA Intern Med. 2014;174(11):18561858.
  3. Health Canada. Proton Pump Inhibitors (antacids): Possible Risk of Clostridium difficile‐Associated Diarrhea. 2012. Available at: http://www.healthycanadians.gc.ca/recall‐alert‐rappel‐avis/hc‐sc/2012/13651a‐eng.php. Accessed February 16, 2015.
  4. Health Canada. Proton Pump Inhibitors: Hypomagnesemia Accompanied by Hypocalcemia and Hypokalemia. 2011. Available at: http://www.hc‐sc.gc.ca/dhp‐mps/medeff/bulletin/carn‐bcei_v21n3‐eng.php#_Proton_pump_inhibitors. Accessed February 16, 2015.
  5. US Food and Drug Administration. FDA Drug Safety Communication: Possible Increased Risk of Fractures of the Hip, Wrist, and Spine With the Use of Proton Pump Inhibitors. 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed February 15, 2015.
  6. US Food and Drug Administration. FDA Drug Safety Communication: Clostridium difficile‐Associated Diarrhea Can Be Associated With Stomach Acid Drugs Known as Proton Pump Inhibitors (PPIs). 2012. Available at: http://www.fda.gov/drugs/drugsafety/ucm290510.htm. Accessed February 15, 2015.
  7. Johnstone J, Nerenberg K, Loeb M. Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):11651177.
  8. Maggio M, Corsonello A, Ceda GP, et al. Proton pump inhibitors and risk of 1‐year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173(7):518523.
  9. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid‐suppressive medication use and the risk for hospital‐acquired pneumonia. JAMA. 2009;301(20):21202128.
  10. Corsonello A, Maggio M, Fusco S, et al. Proton pump inhibitors and functional decline in older adults discharged from acute care hospitals. J Am Geriatr Soc. 2014;62(6):11101115.
  11. Albugeaey M, Alfaraj N, Garb J, Seiler A, Lagu T. Do hospitalists overuse proton pump inhibitors? Data from a contemporary cohort. J Hosp Med. 2014;9(11):731733.
  12. Reid M, Keniston A, Heller JC, Miller M, Medvedev S, Albert RK. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7(5):421425.
  13. Ladd AM, Panagopoulos G, Cohen J, Mar N, Graham R. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347(6):446451.
  14. Zink DA, Pohlman M, Barnes M, Cannon ME. Long‐term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21(10):12031209.
  15. Grant K, Al‐Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28(4):189193.
  16. Breu AC, Allen‐Dicker J, Mueller S, Palamara K, Hinami K, Herzig SJ. Hospitalist and primary care physician perspectives on medication management of chronic conditions for hospitalized patients. J Hosp Med. 2014;9(5):303309.
  17. Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med. 1995;332(3):139142.
  18. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343(5):310316.
  19. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long‐term low‐dose aspirin use. N Engl J Med. 2002;346(26):20332038.
  20. Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):18081825.
  21. Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID‐related ulcer complications. Am J Gastroenterol. 2009;104(3):728738.
  22. Rostom A, Moayyedi P, Hunt R, Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29(5):481496.
  23. van Vliet EP, Steyerberg EW, Otten HJ, et al., The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards. Aliment Pharmacol Ther. 2009;29(2):213221.
  24. Wagner AK, Soumerai SB, Zhang F, Ross‐Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299309.
  25. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid‐suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95(11):31183122.
  26. Mat Saad AZ, Collins N, Lobo MM, O'Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59(1):3134.
  27. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25(5):333340.
  28. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro‐esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205210.
  29. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):6668.
  30. Hamzat H, Sun H, Ford JC, Macleod J, Soiza RL, Mangoni AA. Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. Drugs Aging. 2012;29(8):681690.
  31. Chui D, Young F, Tejani AM, Dillon EC. Impact of academic detailing on proton pump inhibitor prescribing behaviour in a community hospital. Can Pharm J (Ott). 2011;144(2):6671.
  32. Gupta R, Marshall J, Munoz JC, Kottoor R, Jamal MM, Vega KJ. Decreased acid suppression therapy overuse after education and medication reconciliation. Int J Clin Pract. 2013;67(1):6065.
References
  1. IMS Institute for Healthcare Informatics. Medicine Use and Shifting Costs of Healthcare. 2014. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Secure/IIHI_US_Use_of_Meds_for_2013.pdf. Accessed September 26, 2014.
  2. Johansen ME, Huerta TR, Richardson CR. National use of proton pump inhibitors from 2007 to 2011. JAMA Intern Med. 2014;174(11):18561858.
  3. Health Canada. Proton Pump Inhibitors (antacids): Possible Risk of Clostridium difficile‐Associated Diarrhea. 2012. Available at: http://www.healthycanadians.gc.ca/recall‐alert‐rappel‐avis/hc‐sc/2012/13651a‐eng.php. Accessed February 16, 2015.
  4. Health Canada. Proton Pump Inhibitors: Hypomagnesemia Accompanied by Hypocalcemia and Hypokalemia. 2011. Available at: http://www.hc‐sc.gc.ca/dhp‐mps/medeff/bulletin/carn‐bcei_v21n3‐eng.php#_Proton_pump_inhibitors. Accessed February 16, 2015.
  5. US Food and Drug Administration. FDA Drug Safety Communication: Possible Increased Risk of Fractures of the Hip, Wrist, and Spine With the Use of Proton Pump Inhibitors. 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed February 15, 2015.
  6. US Food and Drug Administration. FDA Drug Safety Communication: Clostridium difficile‐Associated Diarrhea Can Be Associated With Stomach Acid Drugs Known as Proton Pump Inhibitors (PPIs). 2012. Available at: http://www.fda.gov/drugs/drugsafety/ucm290510.htm. Accessed February 15, 2015.
  7. Johnstone J, Nerenberg K, Loeb M. Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):11651177.
  8. Maggio M, Corsonello A, Ceda GP, et al. Proton pump inhibitors and risk of 1‐year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173(7):518523.
  9. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid‐suppressive medication use and the risk for hospital‐acquired pneumonia. JAMA. 2009;301(20):21202128.
  10. Corsonello A, Maggio M, Fusco S, et al. Proton pump inhibitors and functional decline in older adults discharged from acute care hospitals. J Am Geriatr Soc. 2014;62(6):11101115.
  11. Albugeaey M, Alfaraj N, Garb J, Seiler A, Lagu T. Do hospitalists overuse proton pump inhibitors? Data from a contemporary cohort. J Hosp Med. 2014;9(11):731733.
  12. Reid M, Keniston A, Heller JC, Miller M, Medvedev S, Albert RK. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med. 2012;7(5):421425.
  13. Ladd AM, Panagopoulos G, Cohen J, Mar N, Graham R. Potential costs of inappropriate use of proton pump inhibitors. Am J Med Sci. 2014;347(6):446451.
  14. Zink DA, Pohlman M, Barnes M, Cannon ME. Long‐term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21(10):12031209.
  15. Grant K, Al‐Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28(4):189193.
  16. Breu AC, Allen‐Dicker J, Mueller S, Palamara K, Hinami K, Herzig SJ. Hospitalist and primary care physician perspectives on medication management of chronic conditions for hospitalized patients. J Hosp Med. 2014;9(5):303309.
  17. Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med. 1995;332(3):139142.
  18. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343(5):310316.
  19. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long‐term low‐dose aspirin use. N Engl J Med. 2002;346(26):20332038.
  20. Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):18081825.
  21. Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID‐related ulcer complications. Am J Gastroenterol. 2009;104(3):728738.
  22. Rostom A, Moayyedi P, Hunt R, Canadian consensus guidelines on long‐term nonsteroidal anti‐inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29(5):481496.
  23. van Vliet EP, Steyerberg EW, Otten HJ, et al., The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards. Aliment Pharmacol Ther. 2009;29(2):213221.
  24. Wagner AK, Soumerai SB, Zhang F, Ross‐Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299309.
  25. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid‐suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95(11):31183122.
  26. Mat Saad AZ, Collins N, Lobo MM, O'Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59(1):3134.
  27. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25(5):333340.
  28. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro‐esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205210.
  29. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):6668.
  30. Hamzat H, Sun H, Ford JC, Macleod J, Soiza RL, Mangoni AA. Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy. Drugs Aging. 2012;29(8):681690.
  31. Chui D, Young F, Tejani AM, Dillon EC. Impact of academic detailing on proton pump inhibitor prescribing behaviour in a community hospital. Can Pharm J (Ott). 2011;144(2):6671.
  32. Gupta R, Marshall J, Munoz JC, Kottoor R, Jamal MM, Vega KJ. Decreased acid suppression therapy overuse after education and medication reconciliation. Int J Clin Pract. 2013;67(1):6065.
Issue
Journal of Hospital Medicine - 10(5)
Issue
Journal of Hospital Medicine - 10(5)
Page Number
281-286
Page Number
281-286
Publications
Publications
Article Type
Display Headline
Reduction of inappropriate exit prescriptions for proton pump inhibitors: A before‐after study using education paired with a web‐based quality‐improvement tool
Display Headline
Reduction of inappropriate exit prescriptions for proton pump inhibitors: A before‐after study using education paired with a web‐based quality‐improvement tool
Sections
Article Source

© 2015 Society of Hospital Medicine

Disallow All Ads
Correspondence Location
Address for correspondence and reprint requests: Todd C. Lee, MD, Royal Victoria Hospital, 687 Pine Avenue West, Room M603B, Montreal, QC Canada H3A1A1; Fax: 514‐843‐1740; E‐mail: todd.lee@mcgill.ca
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Article PDF Media
Media Files